Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032627 · ClinicalTrials.gov registry record · NA
Identifying Targets of Maladaptive Metabolic Responses in Heart Failure
A NA study of Heart Failure, sponsored by AdventHealth Translational Research Institute.
- Active
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT03032627: Active NA study of Heart Failure, sponsored by AdventHealth Translational Research Institute.
NCT03032627 is a NA study of Heart Failure that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 55 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03032627, a NA study of Heart Failure, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the research is to help researchers understand changes in metabolism in patients that develop heart failure.
Primary Outcome
Tissue samples collected during surgery will be analyzed by way of immunoblot and qrtPCR of mRNA for metabolic enzymes on neutralized acid extracts.
Conditions Studied
Interventions
- PROCEDURE Collection of discarded heart tissue
Study Locations (1)
Florida
- Translational Research Institute for Metabolism and Diabetes - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT03032627 still lists
NCT03032627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Collection of discarded heart tissue is the first listed.
NCT03032627 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03032627 about?
NCT03032627 is a clinical study titled "Identifying Targets of Maladaptive Metabolic Responses in Heart Failure". The purpose of the research is to help researchers understand changes in metabolism in patients that develop heart failure.
What is the current status of trial NCT03032627?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2017-03-20. Estimated completion is 2025-12.
What conditions does trial NCT03032627 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03032627?
The interventions under investigation include: Collection of discarded heart tissue (PROCEDURE).
Who is sponsoring clinical trial NCT03032627?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03032627 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03032627's enrollment target sits among peer trials
55 273rd of 397 higher than 124 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI